XML 38 R22.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration, License, and Other Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Revenue from Contract with Customer [Abstract] |
Schedule of collaboration revenue | In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.
Nature/Type of Payment |  | Statement of Operations Presentation
Regeneron's share of profits or losses in connection with commercialization of products |  | Collaboration revenue
Reimbursement for manufacturing of commercial supplies |  | Collaboration revenue
Royalties and/or sales-based milestones earned |  | Collaboration revenue
Reimbursement of Regeneron's research and development expenses |  | Reduction to Research and development expenses
Regeneron's obligation for its share of collaborator's research and development expenses |  | Research and development expense
Up-front and development milestone payments to collaborators |  | Research and development expense
Reimbursement of Regeneron's commercialization-related expenses |  | Reduction to Selling, general, and administrative expense
Regeneron's obligation for its share of collaborator's commercialization-related expenses |  | Selling, general, and administrative expense
Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal |  | Cost of goods sold
Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services) |  | Other operating income
Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:
|  | Statement of Operations Classification |  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  |  | 2020 |  | 2019 |  | 2020 |  | 2019
Antibody: |  |  |  |  |  |  |  |  |  |
Regeneron's share of profits in connection with commercialization of antibodies |  | Sanofi collaboration revenue |  | $ | 212.8 |  |  | $ | 94.2 |  |  | $ | 555.6 |  |  | $ | 105.2 |
Sales-based milestone earned |  | Sanofi collaboration revenue |  | $ | 50.0 |  |  | — |  |  | $ | 50.0 |  |  | — |
Reimbursement for manufacturing of commercial supplies |  | Sanofi collaboration revenue |  | $ | 94.3 |  |  | $ | 85.4 |  |  | $ | 275.0 |  |  | $ | 143.8 |
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 45.5 |  |  | $ | 60.2 |  |  | $ | 174.4 |  |  | $ | 216.5 |
Regeneron's obligation for its share of Sanofi research and development expenses |  | Research and development expense |  | $ | (17.5) |  |  | $ | (10.2) |  |  | $ | (59.1) |  |  | $ | (29.8) |
Reimbursement of commercialization-related expenses |  | Reduction of Selling, general, and administrative expense |  | $ | 83.2 |  |  | $ | 111.6 |  |  | $ | 260.4 |  |  | $ | 349.3 |
Immuno-oncology: |  |  |  |  |  |  |  |  |  |
Regeneron's share of losses in connection with commercialization of Libtayo outside the United States |  | Sanofi collaboration revenue |  | $ | (4.7) |  |  | $ | (4.6) |  |  | $ | (17.3) |  |  | $ | (16.2) |
Reimbursement for manufacturing of commercial supplies |  | Sanofi collaboration revenue |  | $ | 0.9 |  |  | — |  |  | $ | 6.0 |  |  | — |
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 49.8 |  |  | $ | 38.0 |  |  | $ | 136.7 |  |  | $ | 120.9 |
Reimbursement of commercialization-related expenses |  | Reduction of Selling, general, and administrative expense |  | $ | 14.5 |  |  | $ | 3.0 |  |  | $ | 39.2 |  |  | $ | 7.0 |
Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits |  | Cost of goods sold |  | $ | (31.5) |  |  | $ | (20.1) |  |  | $ | (86.5) |  |  | $ | (51.5) |
Amounts recognized in connection with up-front payments received |  | Other operating income |  | $ | 20.0 |  |  | $ | 18.5 |  |  | $ | 57.0 |  |  | $ | 73.8 |
Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:
|  | Statement of Operations Classification |  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  |  | 2020 |  | 2019 |  | 2020 |  | 2019
Regeneron's net profit in connection with commercialization of EYLEA outside the United States |  | Bayer collaboration revenue |  | $ | 287.9 |  |  | $ | 275.0 |  |  | $ | 772.6 |  |  | $ | 793.3 |
Reimbursement for manufacturing of commercial supplies |  | Bayer collaboration revenue |  | $ | 12.0 |  |  | $ | 18.6 |  |  | $ | 52.9 |  |  | $ | 41.5 |
Reimbursement of development expenses |  | Reduction of Research and development expense |  | $ | 11.5 |  |  | $ | 5.0 |  |  | $ | 34.3 |  |  | $ | 15.6 |
Regeneron's obligation for its share of Bayer research and development expenses |  | Research and development expense |  | $ | (12.9) |  |  | $ | (7.0) |  |  | $ | (26.3) |  |  | $ | (13.6) |
Reimbursement of other expenses |  | Cost of collaboration and contract manufacturing |  | $ | 2.0 |  |  | $ | 3.7 |  |  | $ | 5.3 |  |  | $ | 16.6 |
Amounts recognized in our Statements of Operations in connection with the Teva Collaboration Agreement are as follows:
|  | Statement of Operations Classification |  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  |  | 2020 |  | 2019 |  | 2020 |  | 2019
Reimbursement of research and development expenses |  | Reduction of Research and development expense |  | $ | 25.9 |  |  | $ | 34.2 |  |  | $ | 82.1 |  |  | $ | 102.9 |
Amounts recognized in connection with up-front and development milestone payments received |  | Other operating income |  | $ | 17.2 |  |  | $ | 22.8 |  |  | $ | 54.5 |  |  | $ | 68.8 |
Summary of contract balances | The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:
|  | September 30, |  | December 31,
|  | 2020 |  | 2019
Accounts receivable |  | $ | 453.2 |  |  | $ | 272.7 |
Deferred revenue |  | $ | 433.6 |  |  | $ | 328.8 |
The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:
|  | September 30, |  | December 31,
|  | 2020 |  | 2019
Accounts receivable, net |  | $ | (4.5) |  |  | $ | (16.7) |
Deferred revenue |  | $ | 13.6 |  |  | $ | 9.4 |
Other liabilities |  | $ | 441.8 |  |  | $ | 558.6 |
The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:
|  | September 30, |  | December 31,
|  | 2020 |  | 2019
Accounts receivable - other |  | $ | 299.2 |  |  | $ | 311.6 |
Deferred revenue |  | $ | 122.1 |  |  | $ | 123.0 |
The following table summarizes contract balances in connection with the Teva Collaboration Agreement:
|  | September 30, |  | December 31,
|  | 2020 |  | 2019
Accounts receivable - other |  | $ | 26.6 |  |  | $ | 21.2 |
Other liabilities |  | $ | 61.0 |  |  | $ | 114.4 |

X
- Definition Contract With Customer and Collaborator Asset And Liability [Table Text Block] + References No definition available. + Details
Name: | regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock
Namespace Prefix: | regn_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration